HOME >> MEDICINE >> NEWS
Researchers identify leukemia-linked pathway targeted by a new kinase inhibitor

BAR HARBOR, MAINE--Three years ago, using the first of a new class of drugs known as "small molecule kinase inhibitors," medicine slammed shut a door used by cancer. Researchers at The Jackson Laboratory just found another door that kinase inhibitors may close to cancer.

The gene BCR-ABL1 causes two types of leukemia: chronic myelogeneous leukemia (CML) and B-cell acute lymphoblastic leukemia (B-ALL). In both cancers, enzymes that should regulate the growth and development of white blood cells go awry, resulting in uncontrolled growth of the cells. The Swiss-based pharmaceutical company Novartis developed Gleevec, the first kinase inhibitor used to fight cancer by blocking the errant enzyme. It proved effective against chronic phase of CML, but not the advanced phase or against B-ALL. In some patients, it seems CML can develop a resistance to Gleevec.

In the May 2004 issue of Nature Genetics, a research team headed by Shaoguang Li, M.D., Ph.D., of The Jackson Laboratory, announces success with another kinase inhibitor that blocks a different path used by cancer. Studying mice, the researchers discovered that the BCR-ABL1 gene activates three additional enzymes that lead to B-ALL leukemia. One of these enzymes may also be involved when CML patients no longer respond to Gleevec.

"Because of drug resistance, it becomes increasingly difficult to stop progression of and cure this disease by targeting at only one place in a multi-molecule-involved signaling pathway used by cancer," says Dr. Li. "So we needed to find a combined drug therapy targeting simultaneously more than one places in the pathway."

First, the team developed the first efficient and accurate mouse models of both forms of BCR-ABL1-induced leukemia. Next, they discovered that three of the Src kinase class of enzymes are required for B-ALL but not for CML, suggesting that different therapeutic strategies should be used for treating these two diseases although they are induced
'"/>

Contact: Joyce Peterson
joyce@jax.org
207-288-6058
Jackson Laboratory
18-Apr-2004


Page: 1 2

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
(Date:5/26/2015)... Corner, VA (PRWEB) May 26, 2015 ... critical technology and management consulting solutions to the federal ... Technology Strategy and Cloud Solutions. In this newly created ... strategic capabilities and growth in cloud computing, big data, ... join our expanding leadership team as we continue to ...
(Date:5/26/2015)... Norcross, GA (PRWEB) May 26, 2015 ... its line of fresh, all-natural dog foods are now ... Dog Market in Atlanta and The Good Old Dog ... Norcross, Georgia where they’ve recently opened a state-of-the-art, climate ... farmers and farmers’ markets and all of the food ...
(Date:5/26/2015)... New Brunswick (PRWEB) May 26, 2015 ... announce the successful upgrade of the DMi Partners ... This version was the first in Indosoft's contact center ... API improvements, added screen support for such trunk features ... screens, improved lead management, and included upgrades to ...
(Date:5/26/2015)... San Antonio, TX (PRWEB) May 26, 2015 ... announce the opening of its newest clinic on May 25, ... found at 1919 Rogers Road, Suite 102 in Westover Hills ... late as 7 P.M. , “We’re thrilled about opening ... to reach more of our neighbors in San Antonio and ...
(Date:5/26/2015)... 2015 ProTrailer Network is a new ... Pro X . This Effect includes 30 all ... styled text. , ProTrailer Network allows users to ... can easily complement any form of media project. FCPX ... can make professional looking openers. , ProTrailer Network includes ...
Breaking Medicine News(10 mins):Health News:Octo Consulting Group (Octo) Appoints Gaurav “GP” Pal as Vice President of Technology Strategy and Cloud Solutions 2Health News:Allprovide, the All-Natural Pet Food, Available At Georgia Retailers 2Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 2Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 3Health News:TexPTS Announces New Clinic in San Antonio 2Health News:Developers at Pixel Film Studios Release ProTrailer Network for Final Cut Pro X 2
(Date:5/26/2015)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... XIAFLEX ® in the U.S. and XIAPEX ® ... Tom Wegman , will present a corporate overview ... The presentation will take place on Monday, June ... New York, NY . A live webcast of ...
(Date:5/26/2015)... May 26, 2015 ViiV Healthcare, ... (CHAI) announced today that Aurobindo Pharma has submitted an ... Tentative Approval, to the Food and Drug Administration (FDA), ... ANDA for a generic version of dolutegravir, less than ... sale in the United States . ...
(Date:5/26/2015)... Israel , May 26, 2015 /PRNewswire/ ... Dario™ Diabetes Management Solution, announced today that ... leading HMO, Maccabi Healthcare, it has ... as part of Maccabi,s advanced Telecare unit ... diabetes management solution that enables remote treatment ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the Jefferies 2015 Healthcare Conference 2ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 2ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 3ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 4ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 5ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 6ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV 7LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 2LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 3LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 4
Cached News: